PCM
KALV

Pinz Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Pinz Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,000
Closed -$105K – 428
2021
Q3 		$105K Buy
+6,000
New +$122K 0.05% 114
2021
Q2 		– Sell
-4,518
Closed -$116K – 484
2021
Q1 		$116K Buy
+4,518
New +$119K 0.03% 189

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinz Capital Management's KALV Position: Q4 2021 in Review

Pinz Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2021, closing a stake of 6,000 shares — an estimated $105K sold.

Pinz Capital Management first reported a position in KALV in Q1 2021 and held it in 2 quarters. The position peaked at $116K in Q1 2021. 97 funds tracked by Wall St. Rank hold KALV as of Q4 2021.

  • Pinz Capital Management reported no remaining KalVista Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Pinz Capital Management sold 6,000 KalVista Pharmaceuticals shares in Q4 2021, an estimated $105K.
  • Pinz Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Pinz Capital Management's KalVista Pharmaceuticals position peaked at $116K in Q1 2021.
  • 97 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2021.

Based on Pinz Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.